Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Other Operating Expenses: 2023-2024

Historic Other Operating Expenses for Allogene Therapeutics (ALLO) over the last 2 years, with Dec 2024 value amounting to $15.7 million.

  • Allogene Therapeutics' Other Operating Expenses fell 52.25% to $2.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $31.3 million, marking a year-over-year change of. This contributed to the annual value of $15.7 million for FY2024, which is 18.66% up from last year.
  • Per Allogene Therapeutics' latest filing, its Other Operating Expenses stood at $15.7 million for FY2024, which was up 18.66% from $13.2 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Other Operating Expenses registered a high of $15.7 million during FY2024, and its lowest value of $13.2 million during FY2023.
  • Over the past 2 years, Allogene Therapeutics' median Other Operating Expenses value was $14.5 million (recorded in 2023), while the average stood at $14.5 million.
  • Data for Allogene Therapeutics' Other Operating Expenses shows a peak YoY rose of 18.66% (in 2024) over the last 5 years.
  • Over the past 2 years, Allogene Therapeutics' Other Operating Expenses (Yearly) stood at $13.2 million in 2023, then rose by 18.66% to $15.7 million in 2024.